President, Chief Executive Officer, Chief Financial Officer and Director · FATE THERAPEUTICS INC (FATE)

J. Scott Wolchko

A named executive officer of FATE THERAPEUTICS in every fiscal year CompBrief holds from FY2017 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$4,175,069

Salary $675,000Stock awards $34,261Bonus $405,000

FY2023: $3,522,750

1st of 3 named executive officers at Fate Therapeutics by FY2024 total.

3 named officers on file for FATE THERAPEUTICS, FY2024

J. Scott Wolchko’s pay file — $29

  • 8 fiscal years of pay, line by line
  • 7 equity grants, each cited to its filing
  • FATE’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how FATE THERAPEUTICS’s whole pay program stands against its peers

  • FATE THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on FATE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 17, 2025 (DEF 14A).

Free

Get J. Scott Wolchko’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

J. Scott Wolchko compensation by year

FATE THERAPEUTICS Summary Compensation Table · all 8 fiscal years held
In US dollars, as FATE THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Salary$480,000$516,000$540,000$570,000$610,000$645,000$645,000$675,000
Bonus$0$0$0——$0$0$405,000
Stock awards$0$0$4,137,500$1,451,340$9,552,617$0$0$34,261
Option awards$668,789$2,756,998$5,732,955$3,222,577$1,200,000$7,500,000$2,602,350$3,056,208
Non-equity incentive$156,000$258,000$310,500$356,250$366,000$0$270,900$0
Pension and deferred compensation$0$0$0$0$0$0$0$0
All other$0$0$0$0$0$0$4,500$4,600
Total$1,304,789$3,530,998$10,720,955$5,600,167$11,728,617$8,145,000$3,522,750$4,175,069

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: FATE THERAPEUTICS INC DEF 14A filed April 17, 2025, accession 0001193125-25-084310, and prior-year filings. Open the filing on EDGAR.

How this page was built: the FATE THERAPEUTICS INC filed document, accession 0001193125-25-084310. Every figure is read from that document and cited to the page and table it appears in. Filed April 17, 2025.

$1.3M
$3.5M
$10.7M
$5.6M
$11.7M
$8.1M
$3.5M
$4.2M
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY24
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU10,808$17,833—
Option180,558—$6.77
Option347,226—$6.76

Per the Outstanding Equity Awards at Fiscal Year-End table in FATE THERAPEUTICS INC's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

FATE THERAPEUTICS’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
J. Scott Wolchko · this pagePresident, Chief Executive Officer, Chief Financial Officer and Director$4,175,069
Bahram ValamehrChief Research and Development Officer$3,584,600
Cindy TahlChief Legal & Compliance Officer and Corporate Secretary$3,421,100

Board service

FATE THERAPEUTICS board · FY2023

How this board is paid

Company policy: FATE THERAPEUTICS pays directors a $40,000 cash retainer. As stated in FATE THERAPEUTICS's FY2023 proxy.

The full FATE THERAPEUTICS compensation record

free company brief

This page is one person within FATE THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the FATE THERAPEUTICS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are FATE THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

J. Scott Wolchko's compensation dossier · One-time report. No refunds.